Understanding how different prostate tumors develop at a molecular level
Mapping regulatory elements and chromatin structures in prostate tumor subtypes at single nucleosome resolution
This study is looking at how certain parts of our DNA, called enhancers, affect different types of prostate cancer, with the goal of finding better ways to treat patients like you.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-10437895 on NIH RePORTER |
What this research studies
This research investigates the molecular mechanisms that lead to various subtypes of prostate tumors, focusing on the role of regulatory elements known as enhancers. By using advanced techniques like chromatin immunoprecipitation and genome-wide chromosome conformation capture, the study aims to identify specific enhancers and their target genes that are active in different prostate cancer subtypes. This could help in understanding how these tumors behave and progress, ultimately leading to better clinical interventions for patients. The research seeks to develop cost-effective methods to measure enhancer activity and chromatin structures at a high resolution.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with prostate cancer, particularly those with varying tumor subtypes.
Not a fit: Patients with non-malignant prostate conditions or those without a prostate cancer diagnosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more personalized and effective treatments for prostate cancer patients based on their specific tumor subtype.
How similar studies have performed: Other research has shown promise in understanding cancer through the study of regulatory elements, indicating that this approach could yield valuable insights.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Rhie, Suhn Kyong — University of Southern California
- Study coordinator: Rhie, Suhn Kyong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.